Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel Hoos

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
Journal for Immunotherapy of Cancer|July 4, 2024
Impact of isotype on the mechanism of action of agonist anti-OX40 antibodies in cancer: implications for therapeutic combinationsJane E Willoughby, Lang Dou, Sabyasachi Bhattacharya, et al.
Cancer Research Communications|August 18, 2023
Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint BlockadeSapna Yadavilli, Jeremy D Waight, Sara Brett, et al.
The New England Journal of Medicine|June 8, 2010
Improved survival with ipilimumab in patients with metastatic melanomaF Stephen Hodi, Steven J O'Day, David F McDermott, et al.
Journal for Immunotherapy of Cancer|March 17, 2023
First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)Sophie Postel-Vinay, Vincent K Lam, Willeke Ros, et al.
The Lancet. Oncology|December 21, 2019
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 studySagar Lonial, Hans C Lee, Ashraf Badros, et al.
EMBO Molecular Medicine|December 29, 2020
Immunodynamics of explanted human tumors for immuno-oncologyAgathe Dubuisson, Jean-Eudes Fahrner, Anne-Gaëlle Goubet, et al.
Nature|May 31, 2019
Author Correction: Design of amidobenzimidazole STING receptor agonists with systemic activityJoshi M Ramanjulu, G Scott Pesiridis, Jingsong Yang, et al.
Nature|November 9, 2018
Design of amidobenzimidazole STING receptor agonists with systemic activityJoshi M Ramanjulu, G Scott Pesiridis, Jingsong Yang, et al.
Oncotarget|December 25, 2014
Classification of current anticancer immunotherapiesLorenzo Galluzzi, Erika Vacchelli, José-Manuel Bravo-San Pedro, et al.
Journal of Translational Medicine|December 16, 2011
Defining the critical hurdles in cancer immunotherapyBernard A Fox, Dolores J Schendel, Lisa H Butterfield, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
Journal for Immunotherapy of Cancer|July 4, 2024
Impact of isotype on the mechanism of action of agonist anti-OX40 antibodies in cancer: implications for therapeutic combinationsJane E Willoughby, Lang Dou, Sabyasachi Bhattacharya, et al.
Cancer Research Communications|August 18, 2023
Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint BlockadeSapna Yadavilli, Jeremy D Waight, Sara Brett, et al.
The New England Journal of Medicine|June 8, 2010
Improved survival with ipilimumab in patients with metastatic melanomaF Stephen Hodi, Steven J O'Day, David F McDermott, et al.
Journal for Immunotherapy of Cancer|March 17, 2023
First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)Sophie Postel-Vinay, Vincent K Lam, Willeke Ros, et al.
The Lancet. Oncology|December 21, 2019
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 studySagar Lonial, Hans C Lee, Ashraf Badros, et al.
EMBO Molecular Medicine|December 29, 2020
Immunodynamics of explanted human tumors for immuno-oncologyAgathe Dubuisson, Jean-Eudes Fahrner, Anne-Gaëlle Goubet, et al.
Nature|May 31, 2019
Author Correction: Design of amidobenzimidazole STING receptor agonists with systemic activityJoshi M Ramanjulu, G Scott Pesiridis, Jingsong Yang, et al.
Nature|November 9, 2018
Design of amidobenzimidazole STING receptor agonists with systemic activityJoshi M Ramanjulu, G Scott Pesiridis, Jingsong Yang, et al.
Oncotarget|December 25, 2014
Classification of current anticancer immunotherapiesLorenzo Galluzzi, Erika Vacchelli, José-Manuel Bravo-San Pedro, et al.
Journal of Translational Medicine|December 16, 2011
Defining the critical hurdles in cancer immunotherapyBernard A Fox, Dolores J Schendel, Lisa H Butterfield, et al.
Pageof 7